18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors

Journal of Nuclear Medicine

Volumn 51, Issue 6, 2010, Pages 866-874

  Troost, Esther G C ^a   Bussink, Johan ^a   Hoffmann, Aswin L ^a   Boerman, Otto C ^a   Oyen, Wim J G ^a   Kaanders, Johannes H A M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

18F fluorothymidine PET; Adaptive radiotherapy; Dose escalation; Early response monitoring; Head and neck cancer

Indexed keywords

3' FLUOROTHYMIDINE F 18; CISPLATIN; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; CANCER TISSUE; CELL ACTIVITY; CELL PROLIFERATION; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG DOSE ESCALATION; FEMALE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LYMPH NODE METASTASIS; MALE; OROPHARYNX TUMOR; PATIENT MONITORING; PRIMARY TUMOR; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; SIGNAL TRANSDUCTION; TREATMENT INDICATION; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR VOLUME; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; FEASIBILITY STUDY; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE; TIME; TREATMENT OUTCOME;

AGED; CELL PROLIFERATION; DIDEOXYNUCLEOSIDES; FEASIBILITY STUDIES; HUMANS; MALE; MIDDLE AGED; OROPHARYNGEAL NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIATION DOSAGE; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 77953945176     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.069310     Document Type: Article

References (39)

1. Parsons JT, Mendenhall WM, Stringer SP, et al. Squamous cell carcinoma of the oropharynx: surgery, radiation therapy, or both. Cancer. 2002;94:2967-2980.
2. Hunt MA, Zelefsky MJ, Wolden S, et al. Treatment planning and delivery of intensity-modulated radiation therapy for primary nasopharynx cancer. Int J Radiat Oncol Biol Phys. 2001;49:623-632.
3. Kam MK, Chau RM, Suen J, Choi PH, Teo PM. Intensity-modulated radiotherapy in nasopharyngeal carcinoma: dosimetric advantage over conventional plans and feasibility of dose escalation. Int J Radiat Oncol Biol Phys. 2003;56:145-157.
4. Daisne JF, Duprez T, Weynand B, et al. Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology. 2004;233:93-100.
5. Geets X, Lee JA, Bol A, Lonneux M, Gregoire V. A gradient-based method for segmenting FDG-PET images: methodology and validation. Eur J Nucl Med Mol Imaging. 2007;34:1427-1438.
6. Madani I, Duthoy W, Derie C, et al. Positron emission tomography-guided, focal-dose escalation using intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys. 2007;68:126-135.
7. 18F-fluoro-deoxy-glucose- positron emission tomography-based target volume definition in head and neck cancer. Int J Radiat Oncol Biol Phys. 2007;69:1282-1289.
8. Schwartz DL, Ford EC, Rajendran J, et al. FDG-PET/CT-guided intensity modulated head and neck radiotherapy: a pilot investigation. Head Neck. 2005;27:478-487.
9. 18F]FDG-PET) voxel intensity-based intensity-modulated radiation therapy (IMRT) for head and neck cancer. Radiother Oncol. 2006;79:249-258.
10. Maciejewski B, Withers HR, Taylor JM, Hliniak A. Dose fractionation and regeneration in radiotherapy for cancer of the oral cavity and oropharynx: tumor dose-response and repopulation. Int J Radiat Oncol Biol Phys. 1989;16:831-843.
11. Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 1988;27:131-146.
12. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med. 2002;43:1210-1217.
13. Sherley JL, Kelly TJ. Regulation of human thymidine kinase during the cell cycle. J Biol Chem. 1988;263:8350-8358.
14. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334-1336.
15. Shields AF, Mankoff DA, Link JM, et al. Carbon-11-thymidine and FDG to measure therapy response. J Nucl Med. 1998;39:1757-1762.
16. 18F- fluorothymidine. J Radioanal Nucl Chem. 2000;24:843-846.
17. Vogel WV, Wensing BM, van Dalen JA, Krabbe PF, van den Hoogen FJ, Oyen WJ. Optimised PET reconstruction of the head and neck area: improved diagnostic accuracy. Eur J Nucl Med Mol Imaging. 2005;32:1276-1282.
18. Daisne JF, Sibomana M, Bol A, Doumont T, Lonneux M, Gregoire V. Tridimensional automatic segmentation of PET volumes based on measured sourceto-background ratios: influence of reconstruction algorithms. Radiother Oncol. 2003;69:247-250.
19. Dice LR. Measures of the amount of ecologic association between species. Ecology. 1945;26:297-302.
20. Bartko JJ. Measurement and reliability: statistical thinking considerations. Schizophr Bull. 1991;17:483-489.
21. 18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res. 2007;13:3552-3558.
22. 18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging. 2007;34:1339-1347.
23. Pio BS, Park CK, Pietras R, et al. Usefulness of 3'-[F-18]fluoro-3'- deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol. 2006;8:36-42.
24. 18F]3'-deoxy-3'-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol Imaging. 2007;34:878-883.
25. 18F-FLT) in head and neck cancer patients before and early after initiation of chemoradiation therapy. J Nucl Med. 2009;50:1028-1035.
26. 18F-3'-deoxy-3'-fluorothymidine measurements using positron emission tomography. Eur J Nucl Med Mol Imaging. 2009;36:389-395.
27. Pignon JP, le Maitre A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17, 346 patients. Radiother Oncol. 2009;92:4-14.
28. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med. 2007;48:726-735.
29. van Dalen JA, Hoffmann AL, Dicken V, et al. A novel iterative method for lesion delineation and volumetric quantification with FDG PET. Nucl Med Commun. 2007;28:485-493.
30. 18F-FMISO positron emission tomography. Int J Radiat Oncol Biol Phys. 2008;70:1219-1228.
31. Grosu AL, Souvatzoglou M, Roper B, et al. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys. 2007;69:541-551.
32. Lee NY, Mechalakos JG, Nehmeh S, et al. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys. 2008;70:2-13.
33. Rajendran JG, Schwartz DL, O'Sullivan J, et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res. 2006;12:5435-5441.
34. 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer. BMC Cancer. 2005;5:152.
35. Kim JJ, Tannock IF. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer. 2005;5:516-525.
36. Petersen C, Zips D, Krause M, et al. Repopulation of FaDu human squamous cell carcinoma during fractionated radiotherapy correlates with reoxygenation. Int J Radiat Oncol Biol Phys. 2001;51:483-493.
37. Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet. 2006;368:843-854. (Pubitemid 44292807)
38. Overgaard J, Hansen HS, Specht L, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet. 2003;362:933-940. (Pubitemid 37159288)
39. Kaanders JH, Pop LA, Marres HA, et al. ARCON: experience in 215 patients with advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2002;52:769-778.